These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 33227559)

  • 1. A population-based study of hairy cell leukemia over a period of 20 years.
    Wiber M; Maitre E; Poncet JM; Duchenet V; Damaj G; Cornet E; Troussard X
    Cancer Treat Res Commun; 2020; 25():100236. PubMed ID: 33227559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world data on diagnostics, treatment and outcomes of patients with hairy cell leukemia: The HCL-CLLEAR study.
    Panovská A; Žák P; Jurková T; Arpáš T; Brychtová Y; Vašíková A; Hrabčáková V; Prchlíková A; Filipová M; Doubek M
    Hematol Oncol; 2024 May; 42(3):e3280. PubMed ID: 38741354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland.
    Robak T; Błasińska-Morawiec M; Błoński J; Hellmann A; Hałaburda K; Konopka L; Kotlarek-Haus S; Potoczek S; Hansz J; Dmoszyńska A; Urasiński I; Zdziarska B; Dwilewicz-Trojaczek J; Hołowiecki J; Skotnicki AB
    Eur J Haematol; 1999 Jan; 62(1):49-56. PubMed ID: 9918312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patients with relapsed/refractory hairy-cell leukemia.
    Paillassa J; Troussard X
    Cancer Rep (Hoboken); 2022 Mar; 5(3):e1495. PubMed ID: 34250762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up.
    Paillassa J; Cornet E; Noel S; Tomowiak C; Lepretre S; Vaudaux S; Dupuis J; Devidas A; Joly B; Petitdidier-Lionnet C; Haiat S; Mariette C; Thieblemont C; Decaudin D; Validire-Charpy P; Drenou B; Eisenmann JC; Uribe MO; Olivrie A; Touati M; Lambotte O; Hermine O; Karsenti JM; Feugier P; Vaillant W; Gutnecht J; Lippert E; Huysman F; Ghomari K; Boubaya M; Levy V; Riou J; Damaj G; Tanguy-Schmidt A; Hunault-Berger M; Troussard X
    Blood Cancer J; 2020 May; 10(5):62. PubMed ID: 32461544
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second malignancies in patients with hairy cell leukemia in british columbia: a 20-year experience.
    Au WY; Klasa RJ; Gallagher R; Le N; Gascoyne RD; Connors JM
    Blood; 1998 Aug; 92(4):1160-4. PubMed ID: 9694703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Outcomes of Hairy Cell Leukemia Treated With Purine Analogs: A Comparison With the General Population.
    Madanat YF; Rybicki L; Radivoyevitch T; Jagadeesh D; Dean R; Pohlman B; Kalaycio M; Sekeres MA; Smith MR; Hill BT
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):857-862. PubMed ID: 28778620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended follow-up of patients with hairy cell leukemia after treatment with cladribine.
    Goodman GR; Burian C; Koziol JA; Saven A
    J Clin Oncol; 2003 Mar; 21(5):891-6. PubMed ID: 12610190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiology of hairy cell leukemia in Iceland.
    Kristinsson SY; Vidarsson B; Agnarsson BA; Haraldsdottir V; Olafsson O; Johannesson GM; Eyjolfsson GI; Bjornsdottir J; Onundarson PT; Reykdal S
    Hematol J; 2002; 3(3):145-7. PubMed ID: 12111650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term follow-up and second malignancies in 487 patients with hairy cell leukaemia.
    Cornet E; Tomowiak C; Tanguy-Schmidt A; Lepretre S; Dupuis J; Feugier P; Devidas A; Mariette C; Leblond V; Thiéblemont C; Validire-Charpy P; Sutton L; Gyan E; Eisenmann JC; Cony-Makhoul P; Ysebaert L; Troussard X;
    Br J Haematol; 2014 Aug; 166(3):390-400. PubMed ID: 24749839
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term results of alpha interferon as initial therapy and splenectomy as consolidation therapy in patients with hairy cell leukemia. Final report from the Italian Cooperative Group for HCL.
    Federico M; Frassoldati A; Lamparelli T; Foà R; Brugiatelli M; Annino L; Baldini L; Capnist G; Chisesi T; di Celle PF
    Ann Oncol; 1994 Oct; 5(8):725-31. PubMed ID: 7826905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Racial Differences in the Overall Survival of Hairy Cell Leukemia in the United States: A Population-Based Analysis of the Surveillance, Epidemiology, and End Results Database.
    Giri S; Shrestha R; Pathak R; Bhatt VR
    Clin Lymphoma Myeloma Leuk; 2015 Aug; 15(8):484-8. PubMed ID: 25882766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of hairy cell leukemia-variant with cladribine.
    Tetreault SA; Robbins BA; Saven A
    Leuk Lymphoma; 1999 Oct; 35(3-4):347-54. PubMed ID: 10706459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Second cancer risk in hairy cell leukemia: analysis of 350 patients.
    Kurzrock R; Strom SS; Estey E; O'Brien S; Keating MJ; Jiang H; Adams T; Talpaz M
    J Clin Oncol; 1997 May; 15(5):1803-10. PubMed ID: 9164188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series.
    Rosenberg JD; Burian C; Waalen J; Saven A
    Blood; 2014 Jan; 123(2):177-83. PubMed ID: 24192579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients.
    Maloisel F; Benboubker L; Gardembas M; Coiffier B; Divine M; Sebban C; Blanc M; Abgrall JF; Lederlin P; Harousseau JL; Blaise AM; Grosbois B; Morice P; Ghandour C; Castaigne S
    Leukemia; 2003 Jan; 17(1):45-51. PubMed ID: 12529659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial.
    Kreitman RJ; Dearden C; Zinzani PL; Delgado J; Robak T; le Coutre PD; Gjertsen BT; Troussard X; Roboz GJ; Karlin L; Gladstone DE; Kuptsova-Clarkson N; Liu S; Patel P; Rotolo F; Mitry E; Pastan I; Giles F;
    J Hematol Oncol; 2021 Feb; 14(1):35. PubMed ID: 33627164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4+ lymphocytopenia after treatment.
    Bastie JN; Cazals-Hatem D; Daniel MT; D'Agay MF; Rabian C; Glaisner S; Noel-Walter MP; Dabout D; Flandrin G; Dombret H; Poisson D; Degos L; Castaigne S
    Leuk Lymphoma; 1999 Nov; 35(5-6):555-65. PubMed ID: 10609793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biology and Treatment of Hairy Cell Leukemia.
    Paillassa J; Troussard X
    Curr Treat Options Oncol; 2020 Apr; 21(6):44. PubMed ID: 32350628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicenter retrospective analysis regarding the clinical manifestations and treatment results in patients with hairy cell leukemia: twenty-four year Turkish experience in cladribine therapy.
    Hacioglu S; Bilen Y; Eser A; Sivgin S; Gurkan E; Yildirim R; Aydogdu I; Dogu MH; Yilmaz M; Kayikci O; Tombak A; Kuku I; Celebi H; Akay MO; Esen R; Korkmaz S; Keskin A
    Hematol Oncol; 2015 Dec; 33(4):192-8. PubMed ID: 25393847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.